Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Emma Kotisalmi"'
Publikováno v:
Asthma Research and Practice, Vol 6, Iss 1, Pp 1-11 (2020)
Abstract Background Anti-IgE (omalizumab) and anti-IL5/IL5R (reslizumab, mepolizumab and benralizumab) treatments are available for severe allergic and eosinophilic asthma. In these patients, studies have shown beneficial effects in oral corticostero
Externí odkaz:
https://doaj.org/article/d6bb5a91106448a4ac8b79aabfa904b4
Publikováno v:
Asthma Research and Practice, Vol 6, Iss 1, Pp 1-3 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/6b55e6c114ac4c53af06fec6bb3c775a
Publikováno v:
Asthma Research and Practice, Vol 6, Iss 1, Pp 1-3 (2020)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::333f61e0c5b9decbb8945c9e7342c805
http://link.springer.com/article/10.1186/s40733-020-00063-9
http://link.springer.com/article/10.1186/s40733-020-00063-9
Publikováno v:
Asthma research and practice
Asthma Research and Practice
Asthma Research and Practice, Vol 6, Iss 1, Pp 1-11 (2020)
Asthma Research and Practice
Asthma Research and Practice, Vol 6, Iss 1, Pp 1-11 (2020)
Background Anti-IgE (omalizumab) and anti-IL5/IL5R (reslizumab, mepolizumab and benralizumab) treatments are available for severe allergic and eosinophilic asthma. In these patients, studies have shown beneficial effects in oral corticosteroid use an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f313e2a09c096a9c67760e2595501890
http://europepmc.org/articles/PMC7222440
http://europepmc.org/articles/PMC7222440